AnaptysBio, Inc. Common Stock

ANAB trades at a $2.0B market cap while generating no earnings (P/E n/a), suggesting the market is pricing in substantial future value creation rather than current profitability. With RSI at 55.1—right in neutral territory—there's no technical excess, but the 20.42% short interest represents meaningful skepticism from bears. Trading below its 52-week high while maintaining moderate short pressure creates an intriguing dynamic: either shorts are correct about fundamental headwinds, or they're positioned ahead of clinical catalysts that could trigger a squeeze. The pharmaceutical sector's binary risk profile makes this setup depend entirely on pipeline execution rather than valuation anchors.